(AOF) – Abionyx Pharma, a new generation biotech dedicated to the discovery and development of innovative therapies, recorded consolidated half-year sales of 2.1 million euros, after elimination of intra-group transactions. IRIS Pharma recorded half-year sales of 2.4 million euros. As of June 30, 2023, Abionyx Pharma’s cash position stood at €1.9 million before receipt of the CIRs from Abionyx Pharma and IRIS Pharma.
Abionyx Pharma has also announced the development of two innovative technological platforms in ophthalmology: apotherapy based on natural recombinant apolipoprotein alone, and biovectoring which uses the apoA-I complex as a vector to transport different active ingredients.
The company will publish its half-year results on September 28.
© 2023 Agence Option Finance (AOF) – All rights reserved by AOF. AOF collects its data from the sources it considers the most reliable. However, the reader remains solely responsible for their interpretation and for the use of the information made available to them. Thus the reader must hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends with the buttons below.
